Scorpion Sting Envenomation Clinical Trial
Official title:
Prospective, Randomized, Double-Blind, Controlled Study of Alacramyn® vs. Placebo in Pediatric Patients With Systemic Signs of Scorpion Sting Envenomation
There is no FDA approved therapy for the treatment of scorpion envenomation, Centruroides
scorpion envenomation produces a pattern of neurotoxicity with a spectrum of severity ranging
from trivial to life threatening. Patients stung by Centruroides scorpions develop a clinical
syndrome which may require sedation with benzodiazepines and observation for 6 to 28 hours of
intensive care monitoring. A safe therapy is necessary to halt the progression of symptoms
early in the clinical course while avoiding the clinical deterioration that can occur en
route to a tertiary facility. Alacramyn® is anticipated to be safer and more effective than
the present standard of care, midazolam, and faster-acting such that the need for transport
of most rural patients will be eliminated and will reduce hospitalization time.
The working hypotheses are as follows:
1. The investigational antivenom is safe as treatment of scorpion sting envenomation.
2. The investigational antivenom is effective as treatment of scorpion sting envenomation.
The purpose of this Prospective, Randomized, Double-Blind, Controlled, Multicenter Treatment
Protocol, phase III trial is to examine the safety and efficacy of Alacramyn® for treatment
of patients envenomed by scorpion sting.
This study will take place in two pediatric Intensive care units in Tucson, Arizona.
Patients who arrive at the emergency clinic presenting with scorpion sting symptoms will be
evaluated for treatment with respect to the inclusion/exclusion criteria according to the
study procedures. Only patients with clinically important systemic signs of scorpion sting
envenomation will be included in the study. Baseline measures will include severity
evaluation of the scorpion sting envenomation. The patient's vital signs, concomitant
medication, medical history and demographic data will be collected. Blood tests will be done
for haematology, chemistry, venom and anti-venom levels and urine test.
After informed consent and inclusion7exclusion criteria have been obtained and verified, and
the baseline measurements have been done, three vials of Alacramyn® or placebo will be
administered. During the following 3 hours, midazolam will continue, if indicated for control
of agitation.
Patients off midazolam sedation after receiving study drug and no longer manifesting
clinically important systemic signs of scorpion envenomation will be discharge at 4 hours, or
2 hours following cessation of midazolam drip, whichever occurs later. Prior to discharge
repeat lab work, physical assessments, and vital signs will be done. Patients still requiring
midazolam sedation and/or manifesting clinically important systemic signs of scorpion
envenomation will be treated with standard of care for the duration of clinical symptoms.
Those remaining for extended care undergo final study assessments at time of hospital
discharge or at 24 hours after study drug infusion if hospitalization continues.
All patients who participated in the study will be contacted 7 and 14 days after treatment,
looking for symptoms suggestive of ongoing venom effect, delayed serum sickness as well as
for any other adverse event reported by the patient.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00624078 -
Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation
|
Phase 2/Phase 3 | |
| Completed |
NCT01599923 -
Open Label Study of Alacramyn® in Pediatric Patients With Scorpion Sting Envenomation
|
Phase 3 | |
| Completed |
NCT00696683 -
Establishment of Natural History of Scorpion Envenomation
|
N/A | |
| Completed |
NCT01599936 -
Open Label Clinical Trial of Alacramyn® in Pediatric Patients With Scorpion Sting Envenomation
|
Phase 3 |